Novartis talks up potential blockbusters
This article was originally published in Scrip
Executive Summary
With its sweeping revamp now complete, Novartis says it is putting the bulk of its efforts into expanding underlying growth generated from innovative new drugs, many of which have big blockbuster potential. Two are new breakthrough drugs - Cosentyx (secukinumab) and Entresto (sacubitril/valsartan) – while another is the former GlaxoSmithKline oncology asset Promacta (eltrombopag olamine).